Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Average Recommendation of “Hold” from Analysts

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has been assigned an average recommendation of “Hold” from the twenty analysts that are currently covering the company, Marketbeat reports. Five investment analysts have rated the stock with a sell recommendation, six have issued a hold recommendation and nine have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $25.0588.

SRPT has been the subject of several research analyst reports. HC Wainwright reissued a “buy” rating on shares of Sarepta Therapeutics in a report on Tuesday, July 28th. Wolfe Research upgraded Sarepta Therapeutics from a “peer perform” rating to an “outperform” rating and set a $27.00 target price on the stock in a report on Thursday, July 9th. Wall Street Zen cut Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Piper Sandler lowered their price target on Sarepta Therapeutics from $23.00 to $20.00 and set a “neutral” rating for the company in a report on Thursday, July 9th. Finally, Zacks Research raised Sarepta Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 12th.

Sarepta Therapeutics Stock Performance

Shares of NASDAQ:SRPT opened at $20.86 on Monday. The company has a market capitalization of $2.20 billion, a price-to-earnings ratio of -7.19, a P/E/G ratio of 0.32 and a beta of 0.23. The firm’s 50 day simple moving average is $17.73 and its 200 day simple moving average is $18.32. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.42 and a quick ratio of 2.62. Sarepta Therapeutics has a fifty-two week low of $14.68 and a fifty-two week high of $25.32.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.22 by $0.42. Sarepta Therapeutics had a negative net margin of 13.48% and a negative return on equity of 1.60%. The firm had revenue of $401.25 million during the quarter, compared to analysts’ expectations of $366.39 million. During the same quarter in the previous year, the company earned $2.02 earnings per share. The business’s revenue for the quarter was down 34.3% on a year-over-year basis. As a group, sell-side analysts forecast that Sarepta Therapeutics will post 3.43 earnings per share for the current year.

Institutional Trading of Sarepta Therapeutics

A number of large investors have recently bought and sold shares of SRPT. Corient Private Wealth LP lifted its stake in Sarepta Therapeutics by 273.4% in the second quarter. Corient Private Wealth LP now owns 36,712 shares of the biotechnology company’s stock valued at $660,000 after buying an additional 26,880 shares in the last quarter. Amundi acquired a new position in shares of Sarepta Therapeutics in the second quarter valued at approximately $350,000. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in shares of Sarepta Therapeutics during the second quarter worth $518,000. California State Teachers Retirement System increased its position in shares of Sarepta Therapeutics by 1,646.3% during the second quarter. California State Teachers Retirement System now owns 2,107,593 shares of the biotechnology company’s stock worth $37,873,000 after acquiring an additional 1,986,907 shares in the last quarter. Finally, Nykredit A S acquired a new stake in shares of Sarepta Therapeutics during the second quarter worth $43,000. 86.68% of the stock is owned by institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.